Estrogen suppresses the accumulation of senescent cells by promoting BCL-2-independent apoptosis in aged cells. At menopause, this protective effect is lost, leading to accelerated senescent cell accumulation in fat, bone, and cardiovascular tissue. Fisetin fills part of this gap via its BCL-2-targeting senolytic mechanism.

Can fisetin replace hormone replacement therapy (HRT)?

No. HRT acts through estrogen receptor signaling with systemic hormonal effects. Fisetin is a senolytic with anti-inflammatory properties. They address different aspects of aging; some practitioners combine both with physician guidance.

Is there a specific dose for post-menopausal women?

The same 20 mg/kg protocol applies. Monthly (vs quarterly) cycling is more commonly recommended for post-menopausal women given the faster senescent cell reaccumulation rate.